Meta-Analysis

. 2015 Dec;51(18):2792-9.

doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

Douglas B Johnson¹, Alexander M Menzies², Lisa Zimmer³, Zeynep Eroglu⁴, Fei Ye⁵, Shilin Zhao⁵, Helen Rizos⁶, Antje Sucker³, Richard A Scolyer⁷, Ralf Gutzmer⁸, Helen Gogas⁹, Richard F Kefford¹⁰, John F Thompson⁷, Jürgen C Becker¹¹, Carola Berking¹², Friederike Egberts¹³, Carmen Loquai¹⁴, Simone M Goldinger¹⁵, Gulietta M Pupo¹⁶, Willy Hugo¹⁷, Xiangju Kong¹⁷, Levi A Garraway¹⁸, Jeffrey A Sosman⁵, Antoni Ribas¹⁷, Roger S Lo¹⁷, Georgina V Long², Dirk Schadendorf³

Affiliations

¹ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: douglas.b.johnson@vanderbilt.edu.
² Melanoma Institute Australia, Sydney, NSW, Australia; Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
³ Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany.
⁴ Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA; Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA.
⁵ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
⁶ Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia; Macquarie University, Sydney, NSW, Australia.
⁷ Melanoma Institute Australia, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
⁸ Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.
⁹ First Department of Medicine, University of Athens Medical School, Athens, Greece.
¹⁰ Melanoma Institute Australia, Sydney, NSW, Australia; Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia; Macquarie University, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
¹¹ Translational Skin Cancer Research, German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
¹² Department of Dermatology, Ludwig-Maximilians-University, Munich, Germany.
¹³ Department of Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany.
¹⁴ Department of Dermatology, University Medical Center, Mainz, Germany.
¹⁵ Department of Dermatology, University Hospital Zürich, Switzerland.
¹⁶ Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia.
¹⁷ Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
¹⁸ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

PMID: 26608120
PMCID: PMC4666799
DOI: 10.1016/j.ejca.2015.08.022

Meta-Analysis

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

Douglas B Johnson et al. Eur J Cancer. 2015 Dec.

. 2015 Dec;51(18):2792-9.

doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.

Authors

Affiliations

¹ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: douglas.b.johnson@vanderbilt.edu.
² Melanoma Institute Australia, Sydney, NSW, Australia; Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
³ Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany.
⁴ Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA; Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA.
⁵ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
⁶ Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia; Macquarie University, Sydney, NSW, Australia.
⁷ Melanoma Institute Australia, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
⁸ Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany.
⁹ First Department of Medicine, University of Athens Medical School, Athens, Greece.
¹⁰ Melanoma Institute Australia, Sydney, NSW, Australia; Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia; Macquarie University, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
¹¹ Translational Skin Cancer Research, German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
¹² Department of Dermatology, Ludwig-Maximilians-University, Munich, Germany.
¹³ Department of Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany.
¹⁴ Department of Dermatology, University Medical Center, Mainz, Germany.
¹⁵ Department of Dermatology, University Hospital Zürich, Switzerland.
¹⁶ Centre for Cancer Research, The University of Sydney at The Westmead Millennium Institute, Westmead, NSW, Australia.
¹⁷ Department of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
¹⁸ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

PMID: 26608120
PMCID: PMC4666799
DOI: 10.1016/j.ejca.2015.08.022

Abstract

Background: Acquired resistance to BRAF inhibitors (BRAFi) is a near-universal phenomenon caused by numerous genetic and non-genetic alterations. In this study, we evaluated the spectrum, onset, pattern of progression, and subsequent clinical outcomes associated with specific mechanisms of resistance.

Methods: We compiled clinical and genetic data from 100 patients with 132 tissue samples obtained at progression on BRAFi therapy from 3 large, previously published studies of BRAFi resistance. These samples were subjected to whole-exome sequencing and/or polymerase chain reaction-based genetic testing.

Results: Among 132 samples, putative resistance mechanisms were identified in 58%, including NRAS or KRAS mutations (20%), BRAF splice variants (16%), BRAF(V600E/K) amplifications (13%), MEK1/2 mutations (7%), and non-mitogen-activated protein kinase pathway alterations (11%). Marked heterogeneity was observed within tumors and patients; 18 of 19 patients (95%) with more than one progression biopsy had distinct/unknown drivers of resistance between samples. NRAS mutations were associated with vemurafenib use (p = 0.045) and intracranial metastases (p = 0.036), and MEK1/2 mutations correlated with hepatic progression (p = 0.011). Progression-free survival and overall survival were similar across resistance mechanisms. The median survival after disease progression was 6.9 months, and responses to subsequent BRAF and MEK inhibition were uncommon (2 of 15; 13%). Post-progression outcomes did not correlate with specific acquired BRAFi-resistance mechanisms.

Conclusions: This is the first study to systematically characterise the clinical implications of particular acquired BRAFi-resistance mechanisms in patients with BRAF-mutant melanoma largest study to compile the landscape of resistance. Despite marked heterogeneity of resistance mechanisms within patients, NRAS mutations correlated with vemurafenib use and intracranial disease involvement.

Keywords: Acquired; BRAF; Dabrafenib; MAPK; MEK1; Meta-analysis; NRAS; Resistance; Splice; Vemurafenib.

PubMed Disclaimer

Figures

**Figure 1**
**(A)** Number of identified resistance mechanisms per progression sample **(B)** Spectrum of resistance mechanisms in samples with only one identified alteration **(C)** Spectrum of resistance mechanisms in samples with >1 identified alteration co-occurring in the same sample Legend: Green: mutation; Red: amplification; Blue: deletion; ^Distinct *NRAS* mutations identified in different samples

**Figure 2**
Heterogeneity of resistance mechanisms within individual patients with multiple biopsies Legend: Green: mutation; Red: amplification; Blue: deletion; Black: unknown

See this image and copyright information in PMC

References

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. - PubMed
1. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855–867. - PubMed
1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516. - PMC - PubMed
1. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–365. - PubMed
1. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973–977. - PMC - PubMed

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

Affiliations

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous